Eisai To Launch Digestive Drug In Thailand, Add Staff
This article was originally published in PharmAsia News
Eisai plans to increase its sales staff in Thailand as it steps up marketing of its Gasmotin (mosapride) digestive-track drug in Southeast Asia where it has marketing rights. Eisai currently has 10 sales people stationed in Thailand, but expects to begin expanding the staff to 80 to sell the drug expected to be launched by the end of the year. Eisai markets the drug for Dainippon Sumitomo Pharma, its developer. Eisai has applied for approval in Indonesia, Malaysia and The Philippines, and is set to apply in Cambodia, Laos, Myanmar, Singapore, Sri Lanka and Vietnam.(Click here for more - a subscription may be required
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.